| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 196,008 | 174,459 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 76,268 | 108,625 |
| Cash and cash equivalents at beginning of period | 84,362 | - |
| Cash and cash equivalents at end of period | 160,630 | - |
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)